| Publications | PubMed=3756862
Kevin Maynard, Peter G. Parsons;
Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.
Cancer Res. 46:5009-5013(1986) PubMed=9354451
Marina Castellano, Pamela M. Pollock, Marilyn K. Walters, Louise E. Sparrow, Louise M. Down, Brian G. Gabrielli, Peter G. Parsons, Nicholas K. Hayward;
CDKN2A/p16 is inactivated in most melanoma cell lines.
Cancer Res. 57:4868-4875(1997) PubMed=10070891; DOI=10.1038/sj.bjc.6690147; PMCID=PMC2362648
Shuraila Francisca Zerp, Andrea van Elsas, Lucy T.C. Peltenburg, Peter I. Schrier;
p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis.
Br. J. Cancer 79:921-926(1999) PubMed=15048078; DOI=10.1038/sj.onc.1207563
Sandra Pavey, Peter Johansson, Leisl Packer, Jennifer Taylor, Mitchell S. Stark, Pamela M. Pollock, Graeme J. Walker, Glen M. Boyle, Ursula Harper, Sarah-Jane Cozzi, Katherine Hansen ...Show all 20 authors... , Laura Yudt, Chris Schmidt, Peter Hersey, Kay Adrian Oswald Ellem, Michael G.E. O'Rourke, Peter G. Parsons, Paul S. Meltzer, Markus Ringner, Nicholas K. Hayward; Show fewer authors
Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Oncogene 23:4060-4067(2004) PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152
Mitchell S. Stark, Nicholas K. Hayward;
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Cancer Res. 67:2632-2642(2007) PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x
Peter Johansson, Sandra Pavey, Nicholas K. Hayward;
Confirmation of a BRAF mutation-associated gene expression signature in melanoma.
Pigment Cell Res. 20:216-221(2007) PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676
Ken Dutton-Regester, Darryl Irwin, Priscilla Hunt, Lauren G. Aoude, Varsha Tembe, Gulietta M. Pupo, Cathy Lanagan, Candace D. Carter, Linda O'Connor, Michael O'Rourke, Richard Anthony Scolyer ...Show all 15 authors... , Graham J. Mann, Christopher W. Schmidt, Adrian Herington, Nicholas K. Hayward; Show fewer authors
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Mol. Cancer Ther. 11:888-897(2012) PubMed=23039341; DOI=10.1186/1476-4598-11-75; PMCID=PMC3554420
Sara A. Byron, David C. Loch, Candice L. Wellens, Andreas Wortmann, Jia-Yi Wu, John Wang, Kenichi Nomoto, Pamela M. Pollock;
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.
Mol. Cancer 11:75.1-75.15(2012) |
|---|
